ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $669,820 | +132.2% | 31,300 | +404.8% | 0.00% | +100.0% |
Q4 2022 | $288,424 | -55.2% | 6,200 | -50.0% | 0.00% | 0.0% |
Q3 2022 | $643,594 | -88.3% | 12,400 | -90.1% | 0.00% | -87.5% |
Q2 2021 | $5,492,000 | +184.4% | 124,800 | +218.8% | 0.01% | +33.3% |
Q1 2021 | $1,931,000 | +466.3% | 39,147 | +383.3% | 0.01% | +500.0% |
Q4 2020 | $341,000 | -4.5% | 8,100 | +3.8% | 0.00% | 0.0% |
Q3 2020 | $357,000 | -54.5% | 7,800 | -50.0% | 0.00% | -50.0% |
Q2 2020 | $784,000 | +235.0% | 15,600 | +372.7% | 0.00% | +100.0% |
Q4 2018 | $234,000 | -82.1% | 3,300 | -78.4% | 0.00% | -80.0% |
Q3 2018 | $1,308,000 | -35.2% | 15,300 | -12.1% | 0.01% | -37.5% |
Q2 2018 | $2,017,000 | +52.6% | 17,400 | -52.4% | 0.01% | +60.0% |
Q3 2015 | $1,322,000 | +42.3% | 36,590 | +20.6% | 0.01% | +25.0% |
Q1 2015 | $929,000 | -38.7% | 30,350 | +1.8% | 0.00% | -33.3% |
Q4 2014 | $1,515,000 | +211.1% | 29,800 | +142.3% | 0.01% | +200.0% |
Q3 2014 | $487,000 | – | 12,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |